Vitamin D and type 2 diabetes

被引：13

作者：

Eliades M. ^{[1
]}

Pittas A.G. ^{[1
]}

机构：

[1] Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA 02111, 800 Washington Street

来源：

Clinical Reviews in Bone and Mineral Metabolism | 2009年 / 7卷 / 2期

关键词：

Calcium; Type; 2; diabetes; Vitamin D;

D O I：

10.1007/s12018-009-9041-y

中图分类号：

学科分类号：

摘要：

Vitamin D has been reported to have a variety of non-skeletal actions, including on glucose metabolism. There has been increasing evidence from animal and human studies, to suggest that vitamin D may be important in modifying risk of type 2 diabetes. Vitamin D is thought to have both direct (through activation of the vitamin D receptor) and indirect (via regulation of calcium homeostasis) effects on various mechanisms related to the pathophysiology of type 2 diabetes, including pancreatic beta-cell dysfunction, impaired insulin action, and systemic inflammation. The evidence from human studies comes primarily from cross-sectional and a few prospective observational studies showing an inverse association between vitamin D status and prevalence or incidence of type 2 diabetes. While there is paucity of trials that have specifically examined the role of vitamin D in prevention or treatment of type 2 diabetes, vitamin D therapy is emerging as a feasible and cost-effective potential intervention for type 2 diabetes. © Humana Press Inc. 2009.

引用

页码：185 / 198

页数：13

共 96 条

[41]

Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S., Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase, American Journal of Physiology - Endocrinology and Metabolism, 294, 2, (2008)

[42]

Li Y.C., Kong J., Wei M., Chen Z.-F., Liu S.Q., Cao L.-P., 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system, Journal of Clinical Investigation, 110, 2, pp. 229-238, (2002)

[43]

Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., Cohen R., Klopot A., Zhang Z., Yan C.L., 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter, Journal of Biological Chemistry, 282, 41, pp. 29821-29830, (2007)

[44]

Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., Hoogeveen R., Folsom A.R., Heiss G., Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study, Diabetes, 52, 7, pp. 1799-1805, (2003)

[45]

Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E., Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women, Diabetes, 53, 3, pp. 693-700, (2004)

[46]

Pittas A.G., Joseph N.A., Greenberg A.S., Adipocytokines and Insulin Resistance, Journal of Clinical Endocrinology and Metabolism, 89, 2, pp. 447-452, (2004)

[47]

Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, Journal of the American Medical Association, 286, 3, pp. 327-334, (2001)

[48]

Riachy R., Vandewalle B., Conte J.K., Moerman E., Sacchetti P., Lukowiak B., Gmyr V., Bouckenooghe T., Dubois M., Pattou F., 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: Implication of the antiapoptotic protein A20, Endocrinology, 143, 12, pp. 4809-4819, (2002)

[49]

Van Etten E., Mathieu C., Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts, J Steroid Biochem Mol Biol, 97, 1-2, pp. 93-101, (2005)

[50]

Riachy R., Vandewalle B., Moerman E., Belaich S., Lukowiak B., Gmyr V., Muharram G., Kerr C.J., Pattou F., 1,25-dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor, Apoptosis, 11, 2, pp. 151-159, (2006)

← 1 2 3 4 5 6 7 8 9 10 →